CA2184712A1 - Traitement de la nephropathie diabetique a l'aide de valsartan - Google Patents

Traitement de la nephropathie diabetique a l'aide de valsartan

Info

Publication number
CA2184712A1
CA2184712A1 CA002184712A CA2184712A CA2184712A1 CA 2184712 A1 CA2184712 A1 CA 2184712A1 CA 002184712 A CA002184712 A CA 002184712A CA 2184712 A CA2184712 A CA 2184712A CA 2184712 A1 CA2184712 A1 CA 2184712A1
Authority
CA
Canada
Prior art keywords
glomerular
treatment
formula
compound
diabetic nephropathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002184712A
Other languages
English (en)
Inventor
Marc De Gasparo
Nigel Levens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4195481&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2184712(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2184712A1 publication Critical patent/CA2184712A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

On peut utiliser un antagoniste de l'angiotensine II de la formule (I) ainsi que les sels pharmacologiquement acceptables de celui-ci dans le traitement thérapeutique de la néphropathie diabétique.
CA002184712A 1994-03-17 1995-03-07 Traitement de la nephropathie diabetique a l'aide de valsartan Abandoned CA2184712A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH800/94-1 1994-03-17
CH80094 1994-03-17

Publications (1)

Publication Number Publication Date
CA2184712A1 true CA2184712A1 (fr) 1995-09-21

Family

ID=4195481

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002184712A Abandoned CA2184712A1 (fr) 1994-03-17 1995-03-07 Traitement de la nephropathie diabetique a l'aide de valsartan

Country Status (12)

Country Link
EP (1) EP0750500A1 (fr)
JP (1) JPH09510225A (fr)
CN (1) CN1143908A (fr)
AU (1) AU1850695A (fr)
BR (1) BR9507086A (fr)
CA (1) CA2184712A1 (fr)
CZ (1) CZ268896A3 (fr)
FI (1) FI963611A (fr)
HU (1) HUT76542A (fr)
PL (1) PL316259A1 (fr)
SK (1) SK117996A3 (fr)
WO (1) WO1995024901A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69718146T2 (de) * 1996-02-29 2003-10-02 Novartis Ag At1 rezeptor antagonist zur anregung von apoptosis
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
WO1999012534A1 (fr) * 1997-09-10 1999-03-18 Ono Pharmaceutical Co., Ltd. Regulateurs des recepteurs actives par le proliferateur des peroxisomes
EP1870098A3 (fr) * 1998-07-10 2010-07-07 Novartis Ag Utilisation combinée de valsaratan et bloqueurs du canal de calcium à buts thérapeutiques
TR200805275T2 (tr) * 1998-12-23 2008-09-22 Novartis Ag AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
CA2411882C (fr) 2000-06-22 2011-09-06 Novartis Ag Compositions pharmaceutiques
AR032758A1 (es) 2000-07-19 2003-11-26 Novartis Ag Sales valsartan, un proceso para su fabricacion, composiciones farmaceuticas y el uso de dichas sales para la preparacion de medicamentos
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
PE20020617A1 (es) * 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
EP1454625A1 (fr) * 2003-03-06 2004-09-08 Speedel Development AG Pyridylsulfonamidyl-pyrimidines pour le traitement des néphropaties diabétiques
BRPI0416588A (pt) * 2003-11-14 2007-01-30 Novartis Ag uso farmacêutico adicional
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
EP2405899A2 (fr) 2009-03-11 2012-01-18 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Préparations de valsartan

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3026402A1 (de) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
DE122010000024I1 (de) * 1990-02-19 2010-07-08 Novartis Ag Acylverbindungen
US5140037A (en) * 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists
GB9027210D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
IL104755A0 (en) * 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma

Also Published As

Publication number Publication date
HUT76542A (en) 1997-09-29
FI963611A0 (fi) 1996-09-13
WO1995024901A1 (fr) 1995-09-21
FI963611A (fi) 1996-09-13
PL316259A1 (en) 1997-01-06
MX9603999A (es) 1997-12-31
EP0750500A1 (fr) 1997-01-02
BR9507086A (pt) 1997-09-16
CN1143908A (zh) 1997-02-26
AU1850695A (en) 1995-10-03
SK117996A3 (en) 1997-03-05
CZ268896A3 (en) 1997-03-12
JPH09510225A (ja) 1997-10-14
HU9602536D0 (en) 1996-11-28

Similar Documents

Publication Publication Date Title
CA2184712A1 (fr) Traitement de la nephropathie diabetique a l'aide de valsartan
AU2003206738B2 (en) Pharmaceutical compositions comprising valsartan and NEP inhibitors
US20080027032A1 (en) Combinations comprising cox-2 inhibitors and aspirin
JP2002520274A (ja) バルサルタンとカルシウムチャンネルブロッカーの抗高血圧組合わせ
JP5968927B2 (ja) 高血圧と代謝症候群の治療に用いられる薬物組成物及びその応用
JP2008019273A (ja) 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのａｔ１−レセプターアンタゴニスト
RU2239454C2 (ru) Фармацевтическая композиция для предотвращения, лечения или ингибирования развития простой ретинопатии и препролиферирующей ретинопатии
JPH0680629A (ja) 心律動障害の治療のためのアンジオテンシンｉｉ受容体拮抗剤
US20100168193A1 (en) Therapeutic use of imidazole-5-carboxylic acid derivatives
WO1993015732A1 (fr) Traitement du glaucome
WO2006050241A1 (fr) Antagonistes ep4 de la prostaglandine
KR20220016861A (ko) 통풍 또는 고뇨산혈증의 치료약
JP2000264849A (ja) 頻尿・尿失禁治療組成物
WO2014114627A1 (fr) Combinaisons avec de l'acide 2-aminoethanesulfonique
US20220144804A1 (en) Compound for Specifically Enhancing Spatial Coupling Degree of TRPV4-KCa2.3 Complex and Use thereof
US20240051971A1 (en) Intracellular atp enhancer
WO2006002983A1 (fr) Combinaison de composes organiques
MXPA96003999A (en) Treatment of diabetic nephropathy with valsar
WO2010047369A1 (fr) Agent destiné au traitement de la néphropathie diabétique

Legal Events

Date Code Title Description
FZDE Dead